Albertsons (ACI) Q4 Earnings: Resilience Amid Pharmacy Pressures and Solid Guidance
Key Takeaways
- Albertsons reported Q4 fiscal 2025 net sales and other revenue of $20.3 billion, up from $18.8 billion in the prior-year 12-week period, boosted by a 53rd week.
- Identical sales grew 0.7%, pressured by pharmacy headwinds from the Inflation Reduction Act (IRA, a U.S. law capping certain drug prices) and GLP-1 (glucagon-like peptide-1 drugs for diabetes/weight loss) mix shifts.
- Adjusted EBITDA reached $903 million, exceeding expectations despite challenges; full-year adjusted EBITDA hit $3.9 billion.
- Adjusted EPS was $0.48, beating consensus estimates of $0.43 by $0.05.
- Net loss of $481 million due to a $600 million opioid settlement charge; shares fell over 3% post-earnings.
- FY2026 guidance includes identical sales of 0%-1%, adjusted EBITDA of $3.85-$3.925 billion, and raised dividend plus $2 billion buyback authorization.
Earnings Context and Why It Matters to Investors
As someone who follows the grocery and pharmacy space closely, I see Albertsons Companies (ACI)—one of the largest U.S. food and drug retailers with over 2,200 stores—navigating a tough competitive landscape from players like Walmart, Costco, and Amazon. This Q4 fiscal 2025 report, which ended February 28, 2026, wraps up a year marked by macroeconomic pressures, digital acceleration, and regulatory shifts like the IRA affecting reimbursements. From what I see, investors are paying particular attention to pharmacy dynamics, now a critical growth area, and identical sales trends as indicators of consumer health. The strong adjusted profitability highlights operational efficiency, but factors like the opioid settlement and forward guidance will influence perceptions around capital returns and potential mergers in this consolidating industry.
Breaking Down the Reported Results
Albertsons delivered net sales and other revenue of $20.3 billion for the 13-week Q4 fiscal 2025, compared to $18.8 billion in the prior-year 12-week quarter. This uptick included about $1.4 billion from the extra 53rd week, plus 0.7% identical sales growth. Digital sales increased 16%, though pharmacy sales encountered steeper-than-expected headwinds: roughly 105 basis points from IRA pricing and 40 basis points from GLP-1 moderation, totaling around 145 basis points of impact.
Adjusted EBITDA rose to $903.4 million (including about $68 million from the extra week), up from $855.1 million last year and ahead of analyst forecasts. Adjusted net income came in at $252 million, or $0.48 per share, surpassing the consensus of $0.43. On a GAAP basis, though, the company posted a net loss of $480.8 million, or ($0.94) per share, primarily due to a $599.8 million pre-tax opioid settlement charge. For the full year, net sales reached $83.2 billion, up from $80.4 billion, with 2% identical sales growth and adjusted EBITDA of $3.9 billion.
One thing that stands out here is how the adjusted metrics held up well despite the pharmacy pressures—I also checked this using Tickeron’s AI Screener to compare ACI against peers in the industry.
Market Reaction and Investor Sentiment
Post-earnings on April 14, 2026, ACI shares declined 3.03% to $16.34, with further drops in after-hours and premarket trading. The reaction seemed driven by revenue coming in slightly below some estimates (around $20.3 billion versus $20.49 billion expected in certain spots), pharmacy challenges surpassing forecasts, and the opioid charge eclipsing the positive adjusted EPS and EBITDA results. Even with supportive capital return moves—a 13% dividend increase to $0.17 per share and a reset $2 billion buyback—sentiment has turned cautious amid broader grocery sector issues like margin compression.
Forward Outlook and Factors I'm Watching
Looking ahead, Albertsons provided fiscal 2026 guidance for a 53-week year ending around February 2027, forecasting identical sales growth of 0%-1% (or 1.5%-2.5% excluding IRA impacts). This reflects persistent pharmacy reimbursement issues and easing GLP-1 demand.
Adjusted EBITDA is projected at $3.85-$3.925 billion, bolstered by a $2 billion three-year productivity program, AI and digital investments, and supply chain improvements. The adjusted EPS range is $2.22-$2.32, with capital expenditures of $2.0-$2.2 billion earmarked for remodels (94 completed in FY2025), new stores, and technology platforms. The effective tax rate is expected at 24%-25%.
In my view, key areas to monitor include pharmacy trends under the IRA, digital and loyalty program growth (with 49.8 million members previously), fuel margins, and Own Brands performance in an inflationary environment. Capital allocation will remain pivotal—FY2025 returned over $1.8 billion through buybacks and dividends, and the new authorization signals confidence. Broader opportunities could emerge from M&A in the fragmented grocery sector, labor trends, and consumer spending patterns.
Why I Use Tickeron’s AI Screener in My Analysis
As part of my regular research process, I rely on Tickeron’s AI Screener, an AI-powered tool for discovering stocks and ETFs. It lets me filter thousands of assets using customizable criteria like technical patterns, fundamentals, trends, volatility, and AI signals—such as industry peers, market cap, indicators, price patterns, and performance metrics. This helps pinpoint trade ideas, trending stocks, breakouts, and opportunities far more efficiently than manual methods. If you're screening for names like ACI, it's a practical way to streamline your workflow.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
ACI in upward trend: price may jump up because it broke its lower Bollinger Band on September 09, 2026
ACI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 44 cases where ACI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 68%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACI advanced for three days, in 148 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.
The Aroon Indicator entered an Uptrend today. In 104 of 159 cases where ACI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACI as a result. In 54 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 61%.
The Moving Average Convergence Divergence Histogram (MACD) for ACI turned negative on September 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 27 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.
ACI moved below its 50-day moving average on September 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.503) is normal, around the industry mean (3.407). P/E Ratio (72.750) is within average values for comparable stocks, (55.345). Projected Growth (PEG Ratio) (1.212) is also within normal values, averaging (0.979). ACI's Dividend Yield (0.055) is considerably higher than the industry average of (0.014). P/S Ratio (0.080) is also within normal values, averaging (10.259).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. ACI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in production and distribution of thermal coal
Industry FoodRetail
Advertisement